ArticleThe British journal of dermatology2022
The epidemiology of alopecia areata: a population-based cohort study in UK primary care.
Article in The British journal of dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 4 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- A systematic review and meta-synthesis of qualitative studies of alopecia: Managing identity and appearance changes.British journal of health psychology · 2026Pooled it
- Association between alopecia areata and cardiovascular disease: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Epidemiology and burden of alopecia areata in Taiwan: a systematic review.Frontiers in medicine · 2025Pooled it
- Anxiety, depression, and quality of life in children and adults with alopecia areata: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Updated Integrated Safety Analysis of Ritlecitinib up to ~ 5 Years in Patients with Alopecia Areata from the ALLEGRO Clinical Trial Program.American journal of clinical dermatology · 2026Trial
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies.American journal of clinical dermatology · 2026Trial
- Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO-2b/3 and ALLEGRO-LT Clinical Studies for Alopecia Areata.The Journal of dermatology · 2026Trial
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.The Journal of dermatology · 2025Trial
- Describing Patient Characteristics, Treatment Patterns, and Disease Burden Among Patients with Alopecia Areata in Mexico: A Secondary Analysis of the Adelphi Real World Alopecia Areata Disease Specific Programme.Dermatology and therapy · 2026Article
- Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study.Dermatology and therapy · 2026Article
- Global Burden and Future Projections of Alopecia Areata: A Global Burden of Disease Study 2023 Analysis.Journal of clinical medicine · 2026Article
- Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey.Dermatology and therapy · 2026Article
- Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross-Sectional Survey Study.The Australasian journal of dermatology · 2026Article
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care.Journal of clinical medicine · 2026Article
- Non-Invasive Scalp Tape-Strip RNA Sequencing Captures Disease Activity and Treatment-Response Signatures in Alopecia Areata.Allergy · 2026Article
- Localized follicular delivery of a JAK inhibitor using optimized PhosGlyNanoVes: a novel approach for alopecia areata treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata in the United States: Patient Characteristics and Physician Satisfaction According to a Secondary Database Analysis.Dermatology and therapy · 2026Article
- An occupational perspective of the lived experience of individuals with Alopecia Areata: A scoping review.The British journal of occupational therapy · 2026Review
- Retrospective Evaluation of the Impact of the COVID-19 Pandemic on the Incidence of Alopecia Areata in a Single Dermatological Department.Journal of clinical medicine · 2026Article
- Cost-Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan.The Journal of dermatology · 2026Article
Corrections and comments
- Commented on by
- Erratum issuedErrata.2022
Authors and funding
9 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a lack of population-based information on the disease burden and management of alopecia areata (AA).
objectivesTo describe the epidemiology of AA, focusing on incidence, demographics and patterns of healthcare utilization.
methodsPopulation-based cohort study of 4·16 million adults and children, using UK electronic primary care records from the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network database, 2009-2018. The incidence and point prevalence of AA were estimated. Variation in AA incidence by age, sex, deprivation, geographical distribution and ethnicity was examined. Patterns of healthcare utilization were evaluated in people with incident AA.
resultsThe AA incidence rate was 0·26 per 1000 person-years. AA point prevalence in 2018 was 0·58% in adults. AA onset peaked at age 25-29 years for both sexes, although the peak was broader in females. People of nonwhite ethnicity were more likely to present with AA, especially those of Asian ethnicity [incidence rate ratio (IRR) 3·32 (95% confidence interval 3·11-3·55)]. Higher AA incidence was associated with social deprivation [IRR most vs. least deprived quintile 1·47 (1·37-1·59)] and urban living [IRR 1·23 (1·14-1·32)]. People of higher social deprivation were less likely to be referred for specialist dermatology review.
conclusionsBy providing the first large-scale estimates of the incidence and point prevalence of AA, our study helps to understand the burden of AA on the population. Understanding the variation in AA onset between different population groups may give insight into the pathogenesis of AA and its management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.